STATs in cancer inflammation and immunity: a leading role for STAT3

[1]  İ. Reisli,et al.  Defects Along the Th17 Differentiation Pathway Underlie Genetically Distinct Forms of the Hyper IgE Syndrome , 2010 .

[2]  Hua Yu,et al.  In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses , 2009, Nature Biotechnology.

[3]  Cynthia L Sears,et al.  A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses , 2009, Nature Medicine.

[4]  W. Zou,et al.  Endogenous IL-17 contributes to reduced tumor growth and metastasis. , 2009, Blood.

[5]  Hua Yu,et al.  IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway , 2009, The Journal of experimental medicine.

[6]  L. Samavati,et al.  STAT3 tyrosine phosphorylation is critical for interleukin 1 beta and interleukin-6 production in response to lipopolysaccharide and live bacteria. , 2009, Molecular immunology.

[7]  J. Briggs,et al.  Conformationally constrained peptidomimetic inhibitors of signal transducer and activator of transcription. 3: Evaluation and molecular modeling. , 2009, Journal of medicinal chemistry.

[8]  P. Sinha,et al.  Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer 1 , 2009, The Journal of Immunology.

[9]  Hua Yu,et al.  Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. , 2009, Cancer cell.

[10]  D. Banerjee,et al.  Activation of Signal Transducers and Activators of Transcription 3 and Focal Adhesion Kinase by Stromal Cell‐Derived Factor 1 Is Required for Migration of Human Mesenchymal Stem Cells in Response to Tumor Cell‐Conditioned Medium , 2009, Stem cells.

[11]  M. Kaplan,et al.  Impaired development of human Th1 cells in patients with deficient expression of STAT4. , 2009, Blood.

[12]  Ashot Harutyunyan,et al.  A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms , 2009, Nature Genetics.

[13]  J. O’Shea,et al.  Selectivity and therapeutic inhibition of kinases: to be or not to be? , 2009, Nature Immunology.

[14]  C. Divino,et al.  The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. , 2009, Cancer research.

[15]  R. Figlin,et al.  Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. , 2009, Cancer research.

[16]  B. Rini,et al.  Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients , 2009, Clinical Cancer Research.

[17]  Hua Yu,et al.  Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy. , 2009, Cancer research.

[18]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[19]  F. Johnson,et al.  Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding. , 2009, Cancer research.

[20]  M. Karin,et al.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. , 2009, Cancer cell.

[21]  Ozge Canli,et al.  gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. , 2009, Cancer cell.

[22]  C. Drake,et al.  Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. , 2009, Cancer cell.

[23]  R. Jove,et al.  Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. , 2009, Cancer research.

[24]  M. Fujimuro,et al.  Epstein-Barr virus-derived EBNA2 regulates STAT3 activation. , 2009, Biochemical and biophysical research communications.

[25]  C. Sasakawa,et al.  Helicobacter pylori cytotoxin-associated gene A activates the signal transducer and activator of transcription 3 pathway in vitro and in vivo. , 2009, Cancer research.

[26]  S. Imbeaud,et al.  Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours , 2009, Nature.

[27]  Michael Karin,et al.  Is NF-κB a good target for cancer therapy? Hopes and pitfalls , 2009, Nature Reviews Drug Discovery.

[28]  S. Groshen,et al.  Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. , 2009, Cancer research.

[29]  J. Grandis,et al.  Lack of toxicity of a STAT3 decoy oligonucleotide , 2009, Cancer Chemotherapy and Pharmacology.

[30]  Tao Wang,et al.  Effects of the JAK2 Inhibitor, AZ960, on Pim/BAD/BCL-xL Survival Signaling in the Human JAK2 V617F Cell Line SET-2* , 2008, Journal of Biological Chemistry.

[31]  R. Jove,et al.  Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas , 2008, Molecular Cancer Therapeutics.

[32]  Toshio Hirano,et al.  Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. , 2008, Immunity.

[33]  B. Mroczko,et al.  Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients , 2008, Clinical chemistry and laboratory medicine.

[34]  Hua Yu,et al.  Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. , 2008, The Journal of clinical investigation.

[35]  W. Nacken,et al.  Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein , 2008, The Journal of experimental medicine.

[36]  R. Bataille,et al.  Toll-like receptors: lessons to learn from normal and malignant human B cells. , 2008, Blood.

[37]  G. Fuller,et al.  A Novel Inhibitor of Signal Transducers And Activators Of Transcription 3 Activation Is Efficacious Against Established Central Nervous System Melanoma and Inhibits Regulatory T Cells , 2008, Clinical Cancer Research.

[38]  J. O’Shea,et al.  New complexities in helper T cell fate determination and the implications for autoimmune diseases , 2008, Modern rheumatology.

[39]  Xi Zhao,et al.  Stat6 Signaling Suppresses VLA-4 Expression by CD8+ T Cells and Limits Their Ability to Infiltrate Tumor Lesions In Vivo1 , 2008, The Journal of Immunology.

[40]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[41]  G. Trinchieri,et al.  Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells , 2008, The Journal of experimental medicine.

[42]  J. O’Shea,et al.  Therapeutic targeting of Janus kinases , 2008, Immunological reviews.

[43]  J. Karras,et al.  STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. , 2008, Journal of Clinical Investigation.

[44]  W. Paul,et al.  Impaired TH17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome , 2008, Nature.

[45]  T. Macdonald,et al.  Autocrine Regulation of IL-21 Production in Human T Lymphocytes1 , 2008, The Journal of Immunology.

[46]  J. O’Shea,et al.  Th17 cells: a new fate for differentiating helper T cells , 2008, Immunologic research.

[47]  H. Stein,et al.  Aberrant expression of the Th 2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT 3 signaling and attracts Treg cells via regulation of MIP-3 , 2008 .

[48]  J. O’Shea,et al.  Th17 cells: a new fate for differentiating helper T cells , 2008, Immunologic research.

[49]  Lloyd J. Old,et al.  Adaptive immunity maintains occult cancer in an equilibrium state , 2007, Nature.

[50]  W. Gerald,et al.  Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. , 2007, The Journal of clinical investigation.

[51]  M. Wasik,et al.  STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression , 2007, Nature Medicine.

[52]  Liz Y. Han,et al.  Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. , 2007, Cancer research.

[53]  Sheng-Chieh Hsu,et al.  Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. , 2007, Cancer research.

[54]  O. Cummings,et al.  Activation of the signal transducers and activators of the transcription 3 pathway in alveolar epithelial cells induces inflammation and adenocarcinomas in mouse lung. , 2007, Cancer research.

[55]  H. Takada,et al.  Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome , 2007, Nature.

[56]  Katsuaki Sato,et al.  Selective Expansion of Foxp3-Positive Regulatory T Cells and Immunosuppression by Suppressors of Cytokine Signaling 3-Deficient Dendritic Cells1 , 2007, The Journal of Immunology.

[57]  D. Levy,et al.  JAK-STAT Signaling: From Interferons to Cytokines* , 2007, Journal of Biological Chemistry.

[58]  Michael Karin,et al.  References and Notes Supporting Online Material Materials and Methods Som Text Figs. S1 to S6 Tables S1 to S4 Gender Disparity in Liver Cancer Due to Sex Differences in Myd88-dependent Il-6 Production , 2022 .

[59]  Ye Zheng,et al.  Distinct Roles of Different NF-κB Subunits in Regulating Inflammatory and T Cell Stimulatory Gene Expression in Dendritic Cells1 , 2007, The Journal of Immunology.

[60]  G. Stark,et al.  Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. , 2007, Genes & development.

[61]  W. Guida,et al.  Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity , 2007, Proceedings of the National Academy of Sciences.

[62]  R. Agarwal,et al.  Silibinin inhibits inflammatory and angiogenic attributes in photocarcinogenesis in SKH-1 hairless mice. , 2007, Cancer research.

[63]  M. Aziz,et al.  Protein kinase C epsilon, which sensitizes skin to sun's UV radiation-induced cutaneous damage and development of squamous cell carcinomas, associates with Stat3. , 2007, Cancer research.

[64]  K. Shailubhai,et al.  Deactivation of Akt and STAT3 signaling promotes apoptosis, inhibits proliferation, and enhances the sensitivity of hepatocellular carcinoma cells to an anticancer agent, Atiprimod , 2007, Molecular Cancer Therapeutics.

[65]  松村 友美子.  Selective expansion of Foxp3-positive regulatory T cells and immunosuppression by suppressors of cytokine signaling 3-deficient dendritic cells , 2007 .

[66]  Hua Yu,et al.  Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.

[67]  Robert D. Schreiber,et al.  Interferons, immunity and cancer immunoediting , 2006, Nature Reviews Immunology.

[68]  Bianca Sperl,et al.  Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. , 2006, Chemistry & biology.

[69]  A. Baldwin,et al.  Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression , 2006, Oncogene.

[70]  K. Pinkerton,et al.  Receptor‐mediated tobacco toxicity: cooperation of the Ras/Raf‐1/MEK1/ERK and JAK‐2/STAT‐3 pathways downstream of a7 nicotinic receptor in oral keratinocytes , 2006 .

[71]  B. Jenkins,et al.  STAT3 activation regulates growth, inflammation, and vascularization in a mouse model of gastric tumorigenesis. , 2006, Gastroenterology.

[72]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[73]  J. Ritz,et al.  IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. , 2006, Blood.

[74]  D. McConkey,et al.  Src activation of Stat3 is an independent requirement from NF-κB activation for constitutive IL-8 expression in human pancreatic adenocarcinoma cells , 2006, Angiogenesis.

[75]  T. Mcclanahan,et al.  IL-23 promotes tumour incidence and growth , 2006, Nature.

[76]  Y. Kawakami,et al.  The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells , 2006, The Journal of experimental medicine.

[77]  Y. Maehara,et al.  Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. , 2006, Gastroenterology.

[78]  L. Hennighausen,et al.  Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[79]  L. Ivashkiv,et al.  Role of STAT3 in Type I Interferon Responses , 2006, Journal of Biological Chemistry.

[80]  W. Zou.  Regulatory T cells, tumour immunity and immunotherapy , 2006, Nature Reviews Immunology.

[81]  K. Aldape,et al.  Activation of stat3 in human melanoma promotes brain metastasis. , 2006, Cancer research.

[82]  M. Kaplan,et al.  The role of constitutively active Stat6 in leukemia and lymphoma. , 2006, Critical reviews in oncology/hematology.

[83]  J. Turkson,et al.  Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein , 2006, Molecular Cancer Therapeutics.

[84]  Hua Yu,et al.  Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity , 2005, Nature Medicine.

[85]  D. Elashoff,et al.  Cyclooxygenase-2-Dependent Activation of Signal Transducer and Activator of Transcription 3 by Interleukin-6 in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[86]  S. Sebti,et al.  Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. , 2005, Cancer research.

[87]  Michael Karin,et al.  NF-κB: linking inflammation and immunity to cancer development and progression , 2005, Nature Reviews Immunology.

[88]  J. Turkson,et al.  A Novel Platinum Compound Inhibits Constitutive Stat3 Signaling and Induces Cell Cycle Arrest and Apoptosis of Malignant Cells* , 2005, Journal of Biological Chemistry.

[89]  S. Akira,et al.  Stat3 in Resident Macrophages as a Repressor Protein of Inflammatory Response1 , 2005, The Journal of Immunology.

[90]  R. Schreiber,et al.  A critical function for type I interferons in cancer immunoediting , 2005, Nature Immunology.

[91]  K. Sugasawa,et al.  Signal transducer and activator of transcription 3 is a key regulator of keratinocyte survival and proliferation following UV irradiation. , 2005, Cancer research.

[92]  Eric B Haura,et al.  Mechanisms of Disease: insights into the emerging role of signal transducers and activators of transcription in cancer , 2005, Nature Clinical Practice Oncology.

[93]  Sheng-Chieh Hsu,et al.  Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. , 2005, Cancer cell.

[94]  D. Levy,et al.  Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target , 2005, Nature Medicine.

[95]  R. Jove,et al.  Stat3 regulates genes common to both wound healing and cancer , 2005, Oncogene.

[96]  J. Turkson,et al.  Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[97]  R. Arlinghaus,et al.  Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. , 2005, Cancer research.

[98]  J. Turkson,et al.  Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. , 2004, Molecular cancer therapeutics.

[99]  Lin Ying Liu,et al.  IL-5 and Granulocyte-Macrophage Colony-Stimulating Factor Activate STAT3 and STAT5 and Promote Pim-1 and Cyclin D3 Protein Expression in Human Eosinophils1 , 2004, The Journal of Immunology.

[100]  F. Finkelman,et al.  Interleukin‐4‐ and interleukin‐13‐mediated host protection against intestinal nematode parasites , 2004, Immunological reviews.

[101]  Y. Ben-Neriah,et al.  NF-κB functions as a tumour promoter in inflammation-associated cancer , 2004, Nature.

[102]  K. Kiguchi,et al.  Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. , 2004, The Journal of clinical investigation.

[103]  David Baltimore,et al.  One Nucleotide in a κB Site Can Determine Cofactor Specificity for NF-κB Dimers , 2004, Cell.

[104]  Michael Karin,et al.  IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer , 2004, Cell.

[105]  G. Stark,et al.  Cytokine Overexpression and Constitutive NFκB in Cancer , 2004 .

[106]  J. Blattman,et al.  Cancer Immunotherapy: A Treatment for the Masses , 2004, Science.

[107]  W. Greene,et al.  Shaping the nuclear action of NF-κB , 2004, Nature Reviews Molecular Cell Biology.

[108]  W. Reichelt,et al.  Comparison of gene expression in HCT116 treatment derivatives generated by two different 5-fluorouracil exposure protocols , 2004, Molecular Cancer.

[109]  J. Turkson,et al.  Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. , 2004, Molecular cancer therapeutics.

[110]  Hua Yu,et al.  The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.

[111]  Z. Zehner,et al.  Stat3 enhances vimentin gene expression by binding to the antisilencer element and interacting with the repressor protein, ZBP-89 , 2004, Oncogene.

[112]  J. Karras,et al.  Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines. , 2004, Molecular cancer therapeutics.

[113]  J. Pollard.  Tumour-educated macrophages promote tumour progression and metastasis , 2004, Nature Reviews Cancer.

[114]  Hua Yu,et al.  Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells , 2004, Nature Medicine.

[115]  Masato Kubo,et al.  Suppressors of cytokine signaling and immunity , 2003, Nature Immunology.

[116]  Hua Yu,et al.  A critical role for Stat3 signaling in immune tolerance. , 2003, Immunity.

[117]  P. Heinrich,et al.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation. , 2003, The Biochemical journal.

[118]  M. Bartoli,et al.  VEGF differentially activates STAT3 in microvascular endothelial cells , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[119]  J. Karras,et al.  macrophage survival Serine phosphorylation of STAT 3 is essential for Mcl-1 expression and , 2003 .

[120]  M. Lotze,et al.  Interleukin-17 promotes angiogenesis and tumor growth. , 2003, Blood.

[121]  J. Turkson,et al.  Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. , 2003, Cancer research.

[122]  J. Grandis,et al.  Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[123]  E. Fikrig,et al.  STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: A critical role of STAT3 in innate immunity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[124]  G. Trinchieri,et al.  Interleukin-12 and the regulation of innate resistance and adaptive immunity , 2003, Nature Reviews Immunology.

[125]  Hua Yu,et al.  Inhibition of Bcr–Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells , 2002, Oncogene.

[126]  J. Darnell.  Transcription factors as targets for cancer therapy , 2002, Nature Reviews Cancer.

[127]  T. Syrovets,et al.  The Serine Protease Plasmin Triggers Expression of MCP-1 and CD40 in Human Primary Monocytes via Activation of p38 MAPK and Janus Kinase (JAK)/STAT Signaling Pathways* , 2002, The Journal of Biological Chemistry.

[128]  J. Darnell,et al.  Signalling: STATs: transcriptional control and biological impact , 2002, Nature Reviews Molecular Cell Biology.

[129]  Shishinn Sun,et al.  PTEN is a negative regulator of STAT3 activation in human papillomavirus-infected cells. , 2002, The Journal of general virology.

[130]  D. Frank,et al.  The role of STATs in apoptosis. , 2002, Current molecular medicine.

[131]  Michael Karin,et al.  NF-κB in cancer: from innocent bystander to major culprit , 2002, Nature Reviews Cancer.

[132]  Drew M. Pardoll,et al.  Vaccines: Spinning molecular immunology into successful immunotherapy , 2002, Nature Reviews Immunology.

[133]  T. Mak,et al.  The Role of Interleukin 13 in Classical Hodgkin Lymphoma , 2002, Leukemia & lymphoma.

[134]  J. Turkson,et al.  Phosphotyrosyl Peptides Block Stat3-mediated DNA Binding Activity, Gene Regulation, and Cell Transformation* , 2001, The Journal of Biological Chemistry.

[135]  T. Yeatman,et al.  Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[136]  M. Runge,et al.  Thrombin Regulates Vascular Smooth Muscle Cell Growth and Heat Shock Proteins via the JAK-STAT Pathway* , 2001, The Journal of Biological Chemistry.

[137]  E. Vellenga,et al.  c-Jun and c-Fos cooperate with STAT3 in IL-6-induced transactivation of the IL-6 respone element (IRE). , 2001, Cytokine.

[138]  J. Darnell,et al.  Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[139]  S. Akira,et al.  STAT family of transcription factors in cytokine-mediated biological responses. , 2000, Cytokine & growth factor reviews.

[140]  T. Hirano,et al.  Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors , 2000, Oncogene.

[141]  Thomas S. Lin,et al.  STAT signaling in the pathogenesis and treatment of leukemias , 2000, Oncogene.

[142]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[143]  H. Dickensheets,et al.  The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[144]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.

[145]  S. Akira,et al.  Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. , 1999, Immunity.

[146]  J. Grandis,et al.  Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. , 1998, The Journal of clinical investigation.

[147]  G. Stark,et al.  How cells respond to interferons. , 1998, Annual review of biochemistry.

[148]  P. Heinrich,et al.  Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. , 1998, The Biochemical journal.

[149]  J. Darnell.  Studies of IFN-induced transcriptional activation uncover the Jak-Stat pathway. , 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[150]  R. Schreiber,et al.  Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .

[151]  M J May,et al.  NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. , 1998, Annual review of immunology.

[152]  T. Kishimoto,et al.  Gp130 and the interleukin-6 family of cytokines. , 1997, Annual review of immunology.

[153]  Xin-Yuan Fu,et al.  Cell Growth Arrest and Induction of Cyclin-Dependent Kinase Inhibitor p21WAF1/CIP1 Mediated by STAT1 , 1996, Science.

[154]  A. Riggs,et al.  Epigenetic mechanisms of gene regulation , 1996 .

[155]  W. Leonard,et al.  Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. , 1995, Science.

[156]  R. Jove,et al.  Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. , 1995, Science.

[157]  J. Darnell,et al.  Role of STAT2 in the alpha interferon signaling pathway , 1995, Molecular and cellular biology.

[158]  J. Darnell,et al.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.

[159]  S. Akira,et al.  Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway , 1994, Cell.

[160]  J. Darnell,et al.  Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. , 1994, Science.